Curosurf 80 mg

Curosurf 80 mg is a poractant alfa suspension used for respiratory support in premature infants. This intratracheal medication helps improve lung function and reduce respiratory distress.

Curosurf 80 mg is primarily used to treat respiratory distress syndrome (RDS) in premature infants. This condition occurs when the lungs are not fully developed, leading to difficulty in breathing. Poractant alfa, the active ingredient, works by replacing the natural surfactant in the lungs, which helps the lungs expand and function more effectively. What is Curosurf used for? It is specifically designed for intratracheal administration to provide immediate respiratory support.

Common effects of Curosurf 80 mg may include improved lung function and reduced need for mechanical ventilation. Some infants may experience temporary side effects such as mild respiratory discomfort or changes in oxygen levels. These effects are generally monitored and managed by healthcare professionals.

Curosurf 80 mg should be administered only by trained healthcare professionals in a controlled medical setting. It is important to follow proper handling and storage guidelines to maintain the efficacy of the suspension. Always consult a healthcare provider for specific precautions and contraindications.

Curosurf 80 mg may interact with other medications or treatments administered intratracheally. It is important to inform healthcare providers about all current medications to avoid potential interactions. Always follow the advice of a healthcare professional regarding the use of this medication.